Alpha Tau Medical Ltd. (NASDAQ:DRTS) Given Average Recommendation of “Hold” by Brokerages

Alpha Tau Medical Ltd. (NASDAQ:DRTS) has received a consensus rating of “Hold” from the five brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $8.6667.

A number of analysts recently weighed in on DRTS shares. Citigroup upped their target price on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Piper Sandler reissued a “neutral” rating and issued a $5.00 target price on shares of Alpha Tau Medical in a report on Wednesday, March 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Wednesday, January 21st. Zacks Research raised Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Alpha Tau Medical in a research report on Tuesday, March 10th.

Alpha Tau Medical Stock Performance

DRTS opened at $6.86 on Friday. The stock’s 50 day simple moving average is $7.20 and its 200-day simple moving average is $5.42. The company has a current ratio of 7.45, a quick ratio of 7.45 and a debt-to-equity ratio of 0.08. The stock has a market cap of $581.87 million, a PE ratio of -12.94 and a beta of 1.02. Alpha Tau Medical has a 1 year low of $2.30 and a 1 year high of $8.60.

Alpha Tau Medical (NASDAQ:DRTS) last issued its earnings results on Monday, March 9th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Sell-side analysts forecast that Alpha Tau Medical will post -0.45 EPS for the current year.

Institutional Investors Weigh In On Alpha Tau Medical

A number of hedge funds and other institutional investors have recently bought and sold shares of DRTS. Trifecta Capital Advisors LLC acquired a new position in Alpha Tau Medical in the fourth quarter worth $48,000. Envestnet Asset Management Inc. bought a new stake in shares of Alpha Tau Medical during the third quarter worth $62,000. Bank of America Corp DE lifted its position in Alpha Tau Medical by 2,779.1% during the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Alpha Tau Medical by 291.7% in the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after purchasing an additional 17,500 shares during the last quarter. Finally, Millennium Management LLC bought a new position in shares of Alpha Tau Medical in the 3rd quarter valued at about $170,000. 2.65% of the stock is owned by institutional investors and hedge funds.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.